Khloe Kardashian Adds Biohaven Migraine Drug to Brand Touts
(Bloomberg) -- Khloe Kardashian is adding another role to her already busy schedule, migraine ambassador.
The social influencer, who has been criticized for past associations with weight loss teas and smoothies has joined forces with Biohaven Pharmaceutical Holding Co. to promote its migraine medicine, Nurtec ODT. Sales of the tablet in the first quarter were $1.2 million after the drug was approved in February.
Nurtec ODT is seen generating about $50 million in revenue this year and topping $1 billion by 2024, according to the average of analysts’ estimates. Time will tell if its association with a Kardashian will spur the migraine medicine into what the industry calls blockbuster status sooner.
More women suffer from migraines than men, and a smattering of new drugs has offered hope for the often disabling condition. Biohaven faces stiff competition from large-cap drugmakers like Amgen Inc. and the Danish drug company H. Lundbeck A/S. Shares in New Haven Connecticut-based Biohaven rose as much as 3.6% on Wednesday after the announcement.
©2020 Bloomberg L.P.